ArticleOPEN ACCESS

Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma (BMC Cancer, (2022), 22, 1, (543), 10.1186/s12885-022-09654-6)

BMC Cancer
DOI: 10.1186/s12885-022-09692-0
4Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], the authors indicated the following error in the equal contribution section. Only Heng Ma and Peng-hui Feng are cofirst authors.

Cite

CITATION STYLE

APA

Ma, H., Feng, P. H., Yu, S. ni, Lu, Z. H., Yu, Q., & Chen, J. (2022, December 1). Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma (BMC Cancer, (2022), 22, 1, (543), 10.1186/s12885-022-09654-6). BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12885-022-09692-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free